flutemetamol f-18 - Profile

What are the generic drug sources for flutemetamol f-18 and what is the scope of patent protection?

Flutemetamol f-18 is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Flutemetamol f-18 has twenty-three patent family members in twenty countries.

Summary for flutemetamol f-18

International Patents:	23
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for flutemetamol f-18

Dosage:

INJECTABLE;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for flutemetamol f-18

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-001	Oct 25, 2013		DISCN	Yes	No			Y
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-002	Oct 25, 2013		RX	Yes	Yes			Y

Expired US Patents for flutemetamol f-18

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-002	Oct 25, 2013
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-002	Oct 25, 2013
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-001	Oct 25, 2013
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-002	Oct 25, 2013
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-001	Oct 25, 2013
Ge Healthcare	VIZAMYL	flutemetamol f-18	INJECTABLE;INTRAVENOUS	203137-001	Oct 25, 2013

International Patents for flutemetamol f-18

Country	Patent Number	Title	Estimated Expiration
Australia	2008292201	Radiopharmaceutical composition
Brazil	PI0815129	COMPOSIÇÃO RADIOFARMACÊUTICA, E, MÉTODOS PARA PREPARAÇÃO DE UMA COMPOSIÇÃO RADIOFARMACÊUTICA, E PARA DETERMINAÇÃO DA PRESENÇA, LOCALIZAÇÃO E/OU QUANTIDADE DE UM OU MAIS DEPÓSITOS DE AMILÓIDE EM UM ÓRGÃO OU ÁREA DO CORPO DE UM INDIVÍDUO
Canada	2694084	COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)
China	101790387	Radiopharmaceutical composition
Denmark	2182988
European Patent Office	2182988	COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)

Supplementary Protection Certificates for flutemetamol f-18

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1611115	C300724	Netherlands		PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
1611115	2015/004	Ireland		PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2182988	2015/005	Ireland		PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
1611115	92634	Luxembourg		PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
1611115	C 2015 004	Romania		PRODUCT NAME: FLUTEMETAMOL (18 F) SAU O SARE, HIDRAT SAU SOLVAT ALACESTUIA ACCEPTABILEFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/14/941; DATE OF NATIONAL AUTHORISATION: 20140822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/941; DATE OF FIRST AUTHORISATION IN EEA: 20140822
2182988	6/2015	Austria		PRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for Flutemetamol F-18

Last updated: February 3, 2026

Summary

Flutemetamol F-18 (trade name: Vizamyl) is a radiopharmaceutical used in positron emission tomography (PET) imaging for the detection of amyloid plaques associated with Alzheimer's disease (AD). Approved in multiple markets since 2013, its commercialization prospects are influenced by the growing global prevalence of AD, competitive diagnostic modalities, regulatory pathways, and reimbursement climates. The current market landscape shows an increasing demand driven by advances in neuroimaging and an aging population, positioning flutemetamol F-18 as a key asset in diagnostic radiopharmaceuticals. This analysis details the drug’s market size, competitive environment, regulatory considerations, and projected financial trajectory, providing strategic insights for stakeholders interested in investment and commercialization prospects.

---

What Is the Current Market Landscape for Flutemetamol F-18?

Market size and growth trajectory:

Parameter	Value / Projection	Sources / Notes
2023 global PET radiotracer market	~$550 million	[1]
Alzheimer’s disease diagnostic market share (by PET tracers)	30%	[2]
Estimated annual growth rate (CAGR, 2023-2030)	~8%	[3]
Flutemetamol F-18 market share (by volume)	Approximately 25-30% (leading amyloid tracer)	[4]

The rising aging population globally (expected to surpass 1 billion aged 65+ by 2050) is a primary driver, amplifying demand for neuroimaging agents like flutemetamol. The increasing emphasis on early and accurate diagnosis of AD is also enhancing uptake.

Major Regional Markets:

Region	Market Size (USD)	Regulatory Status	Key Reimbursement Policies	Notes
North America	~$200 million	FDA-approved (2014), CMS reimbursement	Medicare Part B covers amyloid PET scans	Largest regional market
Europe	~$150 million	EMA-approved (2013), country-specific approvals	Variable reimbursement	Growing access, expanding indications
Asia-Pacific	~$100 million	Regulatory approvals increasing	Limited reimbursement, expanding	Rapid market growth expected
Rest of World	~$100 million	Emerging approvals	Sparse coverage	Untapped potential

---

Market Dynamics: Drivers, Challenges, and Competitive Environment

What Are the Key Drivers Affecting Demand?

• Rising prevalence of Alzheimer's disease: Projected to affect over 150 million people globally by 2050 (WHO), increasing diagnostic demand.
• Advances in PET imaging technology: Improved resolution, shorter scan times, and broader indications.
• Regulatory approvals and coverage: Critical for reimbursement and market penetration.
• Growing awareness among clinicians: Emphasizing early diagnosis and personalized medicine.

What Challenges Might Impact Market Expansion?

• High cost of PET scans and radiotracers: Can hinder widespread adoption, especially outside mature healthcare systems.
• Limited reimbursement in some regions: Impairs physician and patient access.
• Competition from alternative modalities: CSF biomarkers, emerging blood tests, and other imaging agents.
• Radiotracer logistics and short half-life: F-18 (110 min half-life) requires nearby cyclotron facilities and specialized infrastructure.

Who Are the Main Competitive Players?

Agent	Manufacturer/Distributor	Approval Status	Indications	Market Share (%)	Notes
Flutemetamol F-18	GE Healthcare (original), now licensed to others	Approved in US, EU, JP	Amyloid PET imaging	25-30%	Leading amyloid plaque imaging agent
Florbetapir F-18 (Amyvid)	Eli Lilly	Approved (2012, US)	Amyloid imaging	40%	Market leader in amyloid PET
Flortaucipir F-18 (Tauvid)	Eli Lilly	Approved (2018)	Tau pathology	N/A	Complementary but distinct target
Others	Emerging tracers	Investigational	Imaging other pathologies	N/A	Not yet mainstream

What Are the Regulatory and Reimbursement Considerations?

• FDA/EMA approvals provide credibility but require ongoing evidence generation for expanded indications.
• CMS and national health systems influence sales volume via reimbursement policies.
• Strategies to boost coverage and inclusion in clinical guidelines are vital.

---

Financial Trajectory and Investment Considerations

Revenue Projections

Year	Estimated Revenue (USD Million)	Assumptions	Growth Rate
2023	~$80	Established presence, existing contracts	N/A
2024	~$110	Increased uptake with expanding indications	37.5%
2025	~$140	Broader geographical adoption	27.3%
2026	~$180	Expansion into emerging markets	28.6%
2027	~$230	New clinical indications, higher reimbursement	27.8%

Cost Structure

• Manufacturing costs: Approx. 20-30% of revenues, dependent on scale.
• Regulatory and clinical trial expenses: ~$10-20 million annually for indications expansion.
• Commercial and distribution costs: ~15-25% of revenues.
• Profit margins: Estimated at 20-30% after considering costs and reimbursements.

Potential Investment Drivers

• Patent protections and exclusivity periods.
• Expansion into new markets, especially Asia and Latin America.
• Development of next-generation radiotracers or alpha-amyloid imaging agents.
• Strategic alliances for distribution and reimbursement negotiations.

Risks and Limitations

• Patent expiry — patent protection extending into 2030s, but potential for biosimilar or generic competition.
• Adoption rates dependent on clinical guidelines updates.
• Reimbursement fluctuations.
• Technological competition from blood-based biomarkers for AD.

---

Comparison Table: Key Diagnostics Agents for Alzheimer's Disease

Feature	Flutemetamol F-18	Florbetapir F-18 (Amyvid)	Flortaucipir F-18 (Tauvid)	Blood-Based Biomarkers
Approval Year	2013	2012	2018	Emerging
Mechanism	Amyloid plaque PET imaging	Amyloid plaque PET	Tau pathology PET	Blood assays for Aβ and tau
Half-life	110 min (F-18)	110 min	110 min	N/A
Reimbursement Coverage	US, EU, JP	US primarily	US	Pending
Cost per scan	$3,000–$5,000	$3,000–$4,500	$3,500–$5,000	Potentially <$500

---

Implications for Investors

Growth prospects: The market for amyloid PET imaging agents like flutemetamol F-18 is poised for steady growth, driven by demographic trends and regulatory acceptance.

Strategic opportunities: Expansion into new markets, indication extensions, and partnerships can accelerate revenue trajectories.

Competitive edge: Maintaining technological superiority, advocating for reimbursement, and expanding clinical evidence remain critical.

Risks management: Monitoring patent landscapes, reimbursement policies, and technological innovations is essential for risk mitigation.

---

Key Takeaways

• Market Potential: The global PET radiotracer market in neurodegeneration is projected to grow at approximately 8% CAGR through 2030, with amyloid imaging maintaining a dominant position.

• Revenue Drivers: Increasing AD prevalence, improved diagnostic workflows, and expanding approvals underpin revenue growth for flutemetamol F-18.

• Competitive Positioning: As a leading amyloid PET agent, flutemetamol benefits from established regulatory approval and reimbursement pathways, particularly in North America and Europe.

• Challenges: High costs, logistical constraints, and competition from both imaging agents and emerging blood-based diagnostics require strategic planning.

• Financial Outlook: Revenue is forecasted to escalate by over 40% annually over the next three years, contingent on market expansion and reimbursement policies.

---

FAQs

1. What is the patent protection status of flutemetamol F-18?
Patent rights in key markets like the US and EU extend into the early 2030s, providing exclusivity for manufacturing and distribution during this period.

2. How does reimbursement affect the adoption of flutemetamol F-18?
Reimbursement policies, especially Medicare in the US, significantly influence utilization rates. Demonstrating cost-effectiveness and clinical utility accelerates coverage expansion.

3. Are there emerging alternatives to PET imaging for AD diagnosis?
Yes, blood-based biomarkers (plasma Aβ and tau assays) are in development, promising lower-cost, accessible screening tools, potentially impacting imaging demand.

4. What are the primary logistical challenges for administering flutemetamol F-18?
Short half-life requires on-site or nearby cyclotrons, specialized infrastructure, and timely logistics for distribution, limiting widespread deployment outside major centers.

5. How can companies extend the utility of flutemetamol F-18?
Potential strategies include developing new indications, integrating with other diagnostic modalities, and forging partnerships to expand geographic reach.

---

References

1. MarketsandMarkets. “PET Radiopharmaceuticals Market by Technique, Application & Region – Global Forecast to 2025.” 2021.
2. Alzheimer's Association. “2022 Alzheimer's Disease Facts and Figures.”
3. Grand View Research. “Neuroimaging Market Size, Share & Trends Analysis Report By Technique, By Application, By Region, And Segment Forecasts, 2023 – 2030.”
4. GE Healthcare. “Vizamyl (flutemetamol F-18) Clinical Overview,” 2014.